Saddle pulmonary embolism (SPE) is an acute condition caused by occlusion of a large segment of the pulmonary artery, which can lead to critical consequences for the gas exchange system and the cardiovascular system. This condition is characterized by the formation of a thrombus that detaches from the wall of the deep veins, most often the lower extremities, and moves to the lungs. In this form of embolism, the obstruction occurs at the level of the main pulmonary artery or its branches, which leads to a significant decrease in pulmonary blood flow and the possible development of pulmonary hypertension, shock and death of the patient. Saddle pulmonary embolism requires immediate intervention and can manifest itself with a variety of clinical symptoms, including dyspnea, chest pain and hemoptysis.
History of the disease and interesting historical facts
Saddle pulmonary embolism, as a medical concept, began to be actively studied in the 19th century. One of the first descriptions of something similar refers to the works of the German surgeon A. L. Emil Christopher, who in 1846 discovered the pulmonary arteries during an autopsy of a patient. Since then, scientists have begun to consider the pathogenesis and clinical manifestations of this condition in more detail. In the 20th century, research related to the development of visualization and diagnostic methods, as well as the introduction of anticoagulant therapy, came to the fore, which significantly increased the chances of patient survival. Thus, in the 1970s, CT began to be actively used to diagnose SLE, which served as a breakthrough in understanding this disease.
Epidemiology
The epidemiology of saddle pulmonary embolism shows significant variability by regions and populations. According to international studies, the incidence of SPE ranges from 5 to 30% among all cases of pulmonary embolism. SPE is more common in patients diagnosed with venous thromboembolism, especially in those at high risk: after surgery, trauma or prolonged immobilization. In addition, postmenopausal and pregnant women have an increased incidence, probably due to changes in hemostasis. According to statistics, the mortality rate for SPE reaches 30% without treatment and is about 10% with timely medical intervention.
Genetic predisposition to this disease
Scientific research shows that there is a genetic predisposition to developing blood clots that can lead to saddle pulmonary embolism. It has been established that mutations in several key genes can increase the risk of blood clots, including:
- Von Willebrand factor (F8): Mutations lead to disruption of normal hemostasis function.
- Protein C and C-active protein (PROC): Disturbances in the genes of these proteins can lead to hypercoagulation.
- Leiden Factor 5 (F5): a mutant variant of factor V that increases the risk of venous thrombosis.
- Prothrombin (F2): The g20210A mutation increases prothrombin levels, which also increases the risk of thrombosis.
These mutations can be inherited, necessitating evaluation of family history in patients.
Risk factors for the development of this disease
There are several known risk factors that contribute to the development of saddle pulmonary embolism:
- Long-term immobilization (eg, long trips, surgery).
- Presence of obesity and metabolic disorders.
- Presence of thrombophilic conditions or previous venous thromboembolism.
- Exposure to certain chemicals, such as oral contraceptives.
- Age over 60 years and the presence of concomitant diseases (cardiovascular diseases, cancer).
It is important for healthcare providers to carefully assess all of these risk factors in patients to prevent the development of SLE.
Diagnosis of this disease
Diagnosis of saddle pulmonary embolism involves several key steps:
- Main symptoms: Shortness of breath, chest pain, tachycardia, hemoptysis.
- Laboratory tests: D-dimer tests may indicate the presence of thrombus formation, although they are not highly specific.
- Radiological examinations: Contrast-enhanced CT scan of the lungs is the gold standard for diagnosis, allowing visualization of the presence of a thrombus.
- Other types of diagnostics: Ultrasound examination of veins to detect deep vein thrombosis.
- Differential diagnosis: It is important to rule out other diseases such as myocardial infarction, pneumonia, and other lung diseases.
A comprehensive approach to diagnostics allows for a quick and accurate diagnosis, which is critical for successful treatment.
Treatment
Treatment of saddle pulmonary embolism includes several areas:
- General treatment: Access to oxygen to ensure adequate gas exchange and monitoring of the patient's condition.
- Pharmacological treatment: Anticoagulant therapy, most commonly low molecular weight heparins and vitamin K agonists.
- Surgical treatment: Removal of the thrombus through embolectomy may be indicated in severe cases.
- Other types of treatment: Installation of a cavofilter to prevent recurrent thrombosis if drug therapy is not possible.
Timely intervention can significantly improve the patient's prognosis.
List of medications used to treat this disease
The main drugs used in the treatment of saddle pulmonary embolism include:
- Low molecular weight heparins (eg, Enoxaparin).
- Anticoagulants (Warfarin).
- Direct oral anticoagulants (apixaban, dabigatran).
- Fibrinolytics (streptokinase, tissue plasminogen activator).
The use of drugs depends on the clinical situation and the patient's condition.
Disease monitoring
Monitoring of a patient with saddle pulmonary embolism includes the following aspects:
- Control stages: Regular assessments of functional status, blood oxygen levels and monitoring of hemodynamic parameters.
- Forecast: The prognosis may vary depending on the severity of the embolism and the quality of medical care.
- Complications: Recurrent thrombosis, chronic pulmonary hypertension, and death may occur.
Therefore, monitoring the patient's condition after initial treatment is critical.
Age-related features of the disease
Saddle pulmonary embolism may present differently depending on age group. In older people, it is more often accompanied by comorbidities such as hypertension and diabetes, which may worsen the prognosis. In young people, especially athletes, the development of embolism may be associated with traumatic injuries or excessive physical exertion. It is important to take these age differences into account when conducting diagnosis and treatment.
Questions and Answers
- What is saddle pulmonary embolism? This is an acute condition caused by occlusion of a large pulmonary artery by a thrombus, which can cause critical consequences.
- What are the main causes of saddle pulmonary embolism? The main causes include prolonged immobilization, thrombophilia and trauma.
- How is saddle pulmonary embolism diagnosed? Diagnostics include CLT, ultrasound and D-dimer assessment.
- What are the treatment options for this condition? Treatment includes anticoagulant therapy, surgery and the installation of cavofilters.
- What is the prognosis for saddle pulmonary embolism? The prognosis can vary; without treatment, the mortality rate reaches 30%, and with timely intervention - about 10%.
This information provides a clear understanding of the importance of prompt diagnosis and treatment of saddle pulmonary embolism and its consequences.
